Holmäng S, Hedelin H, Anderström C, Johansson S L
Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden.
J Urol. 1995 Jun;153(6):1823-6; discussion 1826-7.
A retrospective study was done on 176 patients with primary stages Ta and T1 bladder cancer treated between 1963 and 1972. One patient was lost to followup after 6 years, while the remainder were followed to death or for at least 20 years. In 1993, 13 patients had no evidence of disease, 39 died of bladder cancer and 123 died of intercurrent disease. Of 77 patients with a primary noninfiltrating tumor and 99 with a primary lamina propria invasive tumor 9 (11%) and 30 (30%), respectively, died of bladder cancer. Recurrences were noted on 10 or more cystoscopic studies in 16 patients and 10 died of bladder cancer 3.5 to 19 years after the primary transurethral resection. A total of 14 patients received repeated thiotepa instillations, all continued to have recurrences and 10 subsequently died of bladder cancer. Only 1 upper tract tumor was diagnosed on routine followup excretory urography. Invasive transitional cell carcinoma of the bladder developed in only 1 of 59 patients who had been tumor-free for 5 years. The results indicate that patients with recurrences on 10 or more cystoscopic studies will continue to have recurrences until death or cystectomy. Recurrence more than 4 years after the primary tumor operation is another ominous sign. Repeated thiotepa instillations did not influence the course of the disease in patients with a history of multiple recurrences. Followup cystoscopy may be discontinued 5 to 10 years after the last recurrence, at least in patients with a solitary low grade primary tumor. Routine followup urographic studies are neither cost-effective, clinically indicated nor justified in patients with superficial bladder cancer.
对1963年至1972年间接受治疗的176例原发性Ta期和T1期膀胱癌患者进行了回顾性研究。1例患者在6年后失访,其余患者随访至死亡或至少20年。1993年,13例患者无疾病证据,39例死于膀胱癌,123例死于并发疾病。在77例原发性非浸润性肿瘤患者和99例原发性固有层浸润性肿瘤患者中,分别有9例(11%)和30例(30%)死于膀胱癌。16例患者在10次或更多次膀胱镜检查中发现复发,其中10例在初次经尿道切除术后3.5至19年死于膀胱癌。共有14例患者接受了反复的噻替派灌注,均持续复发,其中10例随后死于膀胱癌。在常规随访排泄性尿路造影中仅诊断出1例上尿路肿瘤。在59例已无肿瘤5年的患者中,仅1例发生了浸润性膀胱移行细胞癌。结果表明,在10次或更多次膀胱镜检查中出现复发的患者将继续复发直至死亡或接受膀胱切除术。原发性肿瘤手术后4年以上复发是另一个不祥之兆。反复的噻替派灌注对有多次复发史的患者的疾病进程没有影响。至少在孤立性低级别原发性肿瘤患者中,最后一次复发后5至10年可停止随访膀胱镜检查。对于浅表性膀胱癌患者,常规随访尿路造影检查既不具有成本效益,临床上也无指征且不合理。